Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data; AtaiBeckley Deal Update; ‘Rysanso’ Brand MDMA?
On Tuesday, we covered Compass Pathways’ readout covering 26-week data from its second Phase 3 study of COMP360 psilocybin for treatment-resistant depression (TRD): Compass Closes Out Phase 3 With 6-M...